|
Press Release
Phoenix, AZ (January 12, 2012) – Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults. In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia, possibly one of the most prescribed drugs for this condition. The drug is administered orally and in children there is a significant issue in getting the drug swallowed, due to size of the pill and bad taste. Our sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.
|
|
Read more...
|
|
|
Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual and orodispersable drugs announced today they began trading under symbol KDMP.ob and their new website is
Dr. Hassan Salari, Chairman and CEO, stated, "Kedem is properly capitalized and focused on our goals to commercialize our sublingual drug delivery system. We will further our communication with the public markets in the New Year as business developments are achieved." He added, "The Company has made a number of progress and achievements in its business development through 2011, and will update the shareholders in due course in 2012."
|
|
Read more...
|
November 28, 2011 - Washington D.C., - Today, President Obama took the most significant steps since the Truman Administration to improve the management of federal records. Today's Presidential Memorandum directs agencies to move into a digital-based records keeping system, a move that will save taxpayer dollars, promote accountability, and increase government transparency. Today’s action delivers on a commitment the President made in September 2011 when the White House put forward the Open Government Partnership: National Action Plan for the United States.
|
|
Read more...
|
|
November 28, 2011 - IsoRay, Inc. (Amex: ISR - News) announced today it has shipped its first GliaSite® radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite® radiation therapy system. The GliaSite® radiation therapy system is a balloon catheter device used in the treatment of brain cancer. Having already received FDA clearance, the Washington State regulatory approval opened the door for sales of IsoRay's GliaSite® brain cancer treatment in the United States.
|
|
Read more...
|
|
November 22, 2011 - IsoRay, Inc. (Amex: ISR - News) announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite® radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay’s final regulatory hurdle to commence the sale of its GliaSite® brain cancer treatment in the United States. GliaSite® is a landmark technology that allows physicians to treat more brain cancer patients than ever before with internal radiation or brachytherapy.
|
|
Read more...
|
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 1 of 55 |
